Expanded Access for Repotrectinib
Sponsor
Bristol-Myers Squibb (Industry)
Overall Status
Available
CT.gov ID
NCT05926232
Collaborator
(none)
Study Details
Study Description
Brief Summary
This is an expanded access designed to provide access to Repotrectinib for eligible participants.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Expanded Access
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Bristol-Myers Squibb
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Study Documents (Full-Text)
None provided.More Information
Additional Information:
- BMS Clinical Trial Information
- Pre-Approval Access (PAA) Healthcare Practitioner Requests
- FDA Safety Alerts and Recalls
Publications
None provided.Responsible Party:
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT05926232
Other Study ID Numbers:
- CA127-1057
First Posted:
Jul 3, 2023
Last Update Posted:
Jul 3, 2023
Last Verified:
Jun 1, 2023